The ultimate goal of the Molecular Oncology Program Project (MOPP) is to develop more effective therapies for human cancer based on a better mechanistic understanding of tumor cell survival and drug resistance. The goal will be pursued through close integration of original laboratory studies on molecular mechanisms with innovative clinical trials. To achieve this goal, collaborations between basic scientists and clinical investigators are integral to each research project: MOPP comprises three component research project, three cores, and nine clinical protocols. All the research projects will use myeloma as a paradigm, or model, to study mechanisms of tumor cell survival and treatment response. Observations made in this model will also be extended to other cancers, including breast and ovarian cancer. Project I will investigate the hypothesis that the tumor microenvironment influences drug response by conferring cell adhesion-mediated drug resistance. Myeloma cell lines by adhesion improves treatment response to chemotherapy drugs and radiation. Project II malignant progression through regulation of apoptotic mechanisms that also induce resistance to chemotherapy. This hypothesis will be evaluated in myeloma studies and a phase II clinical trial of neoadjuvant chemotherapy in breast alterations of topoisomerases I and II are involved in drug resistance to inhibitors of these enzymes. Laboratory studies myeloma, AML, NHL, and CLL, as well as certain solid tumors. Research in the component projects will be supported by three cores, including the Administrative Core, the Pathology Core, and the Clinical Trials Core. The MOPP research projects will e significantly enhanced by the highly collaborative nature of these closely integrated laboratory and clinical studies of cancer therapeutics. Results of these studies will provide new insights into the molecular mechanisms of tumor cell killing and drug resistance that will be directly translated into more effective cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA082533-05
Application #
6743654
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
2000-05-01
Project End
2006-04-30
Budget Start
2004-05-05
Budget End
2006-04-30
Support Year
5
Fiscal Year
2004
Total Cost
$1,202,854
Indirect Cost
Name
University of South Florida
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
069687242
City
Tampa
State
FL
Country
United States
Zip Code
33612
Daud, Adil I; Dawson, Jana; DeConti, Ronald C et al. (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res 15:2479-87
Shain, Kenneth H; Yarde, Danielle N; Meads, Mark B et al. (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69:1009-15
Turner, Joel G; Marchion, Douglas C; Dawson, Jana L et al. (2009) Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition. Cancer Res 69:6899-905
Vultur, Adina; Buettner, Ralf; Kowolik, Claudia et al. (2008) SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 7:1185-94
Buettner, Ralf; Huang, Mei; Gritsko, Tanya et al. (2007) Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity. Mol Cancer Res 5:823-32
Nam, Sangkil; Williams, Ann; Vultur, Adina et al. (2007) Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 6:1400-5
Gritsko, Tanya; Williams, Ann; Turkson, James et al. (2006) Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 12:11-9
Turner, Joel G; Gump, Jana L; Zhang, Chunchun et al. (2006) ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood 108:3881-9
Song, Lanxi; Morris, Mark; Bagui, Tapan et al. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542-8
Simon, George R; Lush, Richard M; Gump, Jana et al. (2006) Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther 5:2130-7

Showing the most recent 10 out of 40 publications